La mayoría de las muertes por cáncer no ocurren por el tumor original, sino por células que escapan silenciosamente y despiertan años después en órganos distantes. Un equipo del Hospital Mount Sinai en Nueva York ha descubierto el mecanismo que mantiene a esas células dormidas: la producción de colágeno tipo III, una especie de manto químico que las retiene en estado de hibernación. Publicado en Nature Cancer, este hallazgo no solo explica un misterio que la ciencia había ignorado durante décadas, sino que abre la posibilidad de mantener el cáncer dormido indefinidamente, transformando la form
El Comercio - Perú
· Dec 14, 2021
· health
· 2 min de leitura
High
Apuração: Verificado
Scientists discover why cancer cells can remain dormant for years
Most cancer deaths result from metastasis occurring years after initial diagnosis, making this dormancy mechanism critical to patient survival.
◉
Health & Medicine
2834 artigos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% correspondência
Weight-Loss Drugs Show Promise in Reducing Alcohol Cravings, But Clini…
infobae · 90% correspondência
Granada researchers develop breakthrough treatment for rare pediatric …
Granada Hoy · 90% correspondência
FDA Approves Alzheimer's Drug Amid Expert Skepticism Over Trial Data
infobae · 90% correspondência
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% correspondência
Cobertura Relacionada
La Razón · Aug 24
Expertos advierten sobre la enfermedad mano-pie-boca, infección viral frecuente en verano
La enfermedad mano-pie-boca, causada por enterovirus, es una infección infantil muy contagiosa pero generalmente leve qu…
La Vanguardia · Aug 24 Investigadores crean virus con IA y disparan alertas sobre bioseguridadInvestigadores de Stanford utilizaron IA para crear 16 virus bacteriófagos sintéticos, generando preocupaciones sobre la…
OkDiario · Aug 24 La inflamación aguda es necesaria; el problema surge cuando se cronificaUna farmacéutica explica que la inflamación aguda es esencial para la defensa del organismo, pero cuando se cronifica se…
The Objective · Aug 24 El chikungunya triplica sus casos en España con 119 positivos detectados este añoEspaña registra 119 casos de chikungunya en 2026, triplicando los 42 del año anterior, todos importados pero elevando la…
Impacto Geopolítico
🌎
Medical research discovery on cancer cell dormancy has no direct geopolitical implications; it represents scientific advancement benefiting global health rather than affecting international relations.
Escalation Risk
low
Confidence
HIGH
No power dynamics shift. This is a biomedical research finding from a U.S. institution with universal health applications.
Viés e Enquadramento
⚖
Straightforward science reporting on cancer dormancy research with minimal bias; presents findings and therapeutic implications in neutral, factual language without sensationalism.
Bias Direction
center
Confidence
HIGH
Standard scientific journalism framing: presents research findings, institutional credibility (Mount Sinai), peer-reviewed publication (Nature Cancer), and expert attribution to establish authority and reliability.
Skeptical or cautionary scientific voices questioning the research methodology or clinical applicability
Timeline for potential therapeutic applications or realistic expectations for patients
Perspectives from other research institutions or competing theories on tumor dormancy
Patient or oncologist perspectives on the practical implications of these findings
Lente Econômica
📈
Mount Sinai researchers discover type III collagen enables cancer cell dormancy, potentially enabling new therapeutic interventions to prevent metastasis and tumor recurrence through targeted drug development.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Diagnostic and laboratory services
Medical research and development
Patients with cancer could benefit from improved treatment options that prevent metastasis and recurrence, potentially extending survival rates and reducing mortality. Healthcare costs may decrease long-term if preventive therapies prove effective, though initial treatment costs may increase during development and adoption phases.
Regulatory agencies (FDA, EMA, COFEPRIS in Peru) will need to establish pathways for accelerated approval of collagen-based therapeutics. Healthcare systems should prepare for potential integration of new biomarkers for tumor recurrence prediction into standard cancer screening protocols. Research funding priorities may shift toward dormancy biology and latency-inducing therapies.